Table 1.

Distribution of tumor characteristics and menopausal hormone therapy use by major invasive histologic type

Ductal n = 2,224*
Lobular/tubular n = 765
Mixed ductal-lobular n = 151
n (%)n (%)n (%)
Grade
1388 (17.4)178 (23.3)24 (15.9)
21,070 (48.1)501 (65.5)95 (62.9)
3+759 (34.1)81 (10.6)32 (21.2)
Unknown7 (0.3)5 (0.7)0 (0.0)
Size
TI1,250 (56.2)429 (56.1)84 (55.6)
T2775 (34.8)251 (32.8)57 (37.7)
T3+122 (5.5)64 (8.4)6 (4.0)
Unknown§77 (3.5)21 (2.7)4 (2.6)
Nodes
01,368 (61.5)489 (63.9)94 (62.3)
1524 (23.6)155 (20.3)37 (24.5)
2+203 (9.1)70 (9.2)13 (8.6)
Unknown§129 (5.8)51 (6.7)7 (4.6)
ER/PR status
ER+ and/or PR+1,718 (77.2)712 (93.1)138 (91.4)
ER− and PR−481 (21.6)38 (5.0)9 (6.0)
Unknown25 (1.1)15 (2.0)4 (2.6)
Her2/neu
Negative1,536 (69.1)609 (79.6)111 (73.5)
Positive461 (20.7)85 (11.1)27 (17.9)
Unknown227 (10.2)71 (9.3)13 (8.6)
Use of hormone therapy
Never804 (36.1)174 (22.7)44 (28.8)
Ever1,420 (63.7)591 (77.0)107 (69.9)
Current944 (42.4)437 (56.9)83 (54.2)
Unknown5 (0.2)3 (0.4)2 (1.3)
  • * n, number among that histologic type for which data on hormone therapy status were available.

  • 1, well-differentiated (low grade); 2, moderately differentiated (intermediate grade); 3+, poorly differentiated or undifferentiated (high grade).

  • T1, ≤2 cm; T2, >2 to ≤5 cm; T3+, >5 cm.

  • § High proportion of missing values due to lack of preoperative data on size and nodal status for cases exposed to neoadjuvant chemotherapy.

  • Includes cases with unknown hormone therapy status, thus making the total number higher than that given in each column head. In addition, the total number of cases with complete hormone therapy data does not total 3,234, due to the exclusion of all other histological types.

  • For controls, current use of hormone therapy was n = 2205.